GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Big Pharma Split Corp (TSX:PRM) » Definitions » Profitability Rank

Big Pharma Split (TSX:PRM) Profitability Rank : 7 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Big Pharma Split Profitability Rank?

Big Pharma Split has the Profitability Rank of 7.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Big Pharma Split's Operating Margin % for the quarter that ended in Dec. 2023 was 0.00%. As of today, Big Pharma Split's Piotroski F-Score is 5.


Competitive Comparison of Big Pharma Split's Profitability Rank

For the Asset Management subindustry, Big Pharma Split's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Big Pharma Split's Profitability Rank Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, Big Pharma Split's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Big Pharma Split's Profitability Rank falls into.



Big Pharma Split Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Big Pharma Split has the Profitability Rank of 7.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Big Pharma Split's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0 / 0.414
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Big Pharma Split has an F-score of 5 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Big Pharma Split Profitability Rank Related Terms

Thank you for viewing the detailed overview of Big Pharma Split's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Big Pharma Split (TSX:PRM) Business Description

Traded in Other Exchanges
Address
610 Chartwell Road, Suite 204, Oakville, ON, CAN, L6J 4A5
Big Pharma Split Corp is a mutual fund corporation. Its investment objective is to provide shareholders with fixed cumulative preferential quarterly cash distributions, and regular monthly cash distributions. The company has a presence in the United States; Switzerland; France and United Kingdom.
Executives
Michael Kovacs Director, Senior Officer

Big Pharma Split (TSX:PRM) Headlines